Therapeutic effect of centchroman alone and in combination with glycine soya on 7,12-dimethylbenz[α]anthracene-induced breast tumor in rat

Food and Chemical Toxicology

Volumn 48, Issue 6, 2010, Pages 1587-1591

  Mishra, Rajeev ^a   Tiwari, Ashutosh ^b   Bhadauria, Smrati ^a   Mishra, Jyoti ^c   Murthy, P K ^a   Murthy, P S R ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b University of Wisconsin Milwaukee   (United States)

^c INDIAN INSTITUTE OF PULSES RESEARCH   (India)

Author keywords

Apoptosis; Breast cancer; Centchroman; Estrogen receptor; Glycine soya

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; CENTCHROMAN; GLYCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER REGRESSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; IMMUNOHISTOCHEMISTRY; NONHUMAN; OPTIMAL DRUG DOSE; RAT; SOYBEAN; TUMOR BIOPSY;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; APOPTOSIS; CARCINOGENS; CELL PROLIFERATION; CENTCHROMAN; ESTROGEN ANTAGONISTS; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN; SOYBEANS;

RATTUS;

EID: 77952878089     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fct.2010.03.029     Document Type: Article

References (28)

1. Boue S.M., Tilghman S.L., Elliott S., Zimmerman M.C., Williams K.Y., Payton-Stewart F., Miraflor A.P., Howell M.H., Shih B.Y., Carter-Wientjes C.H., Segar C., Beckman B.S., Wiese T.E., Cleveland T.E., McLachlan J.A., Burow M.E. Identification of the potent phytoestrogen glycinol in elicited soybean (Glycine max). Endocrinology 2009, 150:2446-2453.
2. Cohen L.A., Pittman B., Wang C.X., Aliaga C., Yu L., Moyer J.D. LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model. Cancer Res. 2001, 61:8683-8688.
3. Constantinou A.I., White B.E., Tonetti D., Yang Y., Liang W., Li W., van Breemen R.B. The soy isoflavone daidzein improves the capacity of tamoxifen to prevent mammary tumours. Eur. J. Cancer 2005, 41:647-654.
4. Doisneau-Sixou S.F., Sergio C.M., Carroll J.S., Hui R., Musgrove E.A., Sutherland R.L. Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr. Relat. Cancer 2003, 10:179-186.
5. Fisher B., Costantino J.P., Redmond C.K., Fisher E.R., Wickerham D.L., Cronin W.M. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 1994, 86:527-537.
6. Fisher B., Costantino J.P., Wickerham D.L., Cecchini R.S., Cronin W.M., Robidoux A., Bevers T.B., Kavanah M.T., Atkins J.N., Margolese R.G., Runowicz C.D., James J.M., Ford L.G., Wolmark N. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl. Cancer Inst. 2005, 97:1652-1662.
7. Ganry O. Phytoestrogen and breast cancer prevention. Eur. J. Cancer Prev. 2002, 11:519-522.
8. Giri A.K., Mukhopadhyay A., Sun J., Hsie A.W., Ray S. Antimutagenic effects of centchroman - a contraceptive and a candidate drug for breast cancer in multiple mutational assays. Mutagenesis 1999, 14:613-620.
9. Harrell J.C., Dye W.W., Allred D.C., Jedlicka P., Spoelstra N.S., Sartorius C.A., Horwitz K.B. Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. Cancer Res. 2006, 66:9308-9315.
10. Huggins C., Yang N.C. Induction and extinction of mammary cancer. A striking effect of hydrocarbons permits analysis of mechanisms of causes and cure of breast cancer. Science 1962, 137:257-262.
11. Kim S.Y., Laxmi Y.R., Suzuki N., Ogura K., Watabe T., Duffel M.W., Shibutani S. Formation of tamoxifen-DNA adducts via O-sulfonation, not O-acetylation, of alpha-hydroxytamoxifen in rat and human livers. Drug Metab. Dispos. 2005, 33:1673-1678.
12. Lawrence J.A., Malpas P.B., Sigman C.C., Kelloff G.J. Clinical development of estrogen modulators for breast cancer chemoprevention in premenopausal vs. postmenopausal women. J. Cell Biochem. Suppl 2000, 34:103-114.
13. Lawry J. Detection of apoptosis by the TUNEL assay. Methods Mol. Med. 2004, 88:183-190.
14. Lupien M., Eeckhoute J., Meyer C.A., Krum S.A., Rhodes D.R., Liu X.S., Brown M. Coactivator function defines the active estrogen receptor alpha cistrome. Mol. Cell Biol. 2009, 29:3413-3423.
15. Mense S.M., Hei T.K., Ganju R.K., Bhat H.K. Phytoestrogens and breast cancer prevention: possible mechanisms of action. Environ. Health Perspect. 2008, 116:426-433.
16. Namba R., Young L.J., Maglione J.E., McGoldrick E.T., Liu S., Wurz G.T., DeGregorio M.W., Borowsky A.D., MacLeod C.L., Cardiff R.D., Gregg J.P. Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ. Breast Cancer Res. 2005, 7:R881-R889.
17. Nigam M., Ranjan V., Srivastava S., Sharma R., Balapure A.K. Centchroman induces G0/G1 arrest and caspase-dependent apoptosis involving mitochondrial membrane depolarization in MCF-7 and MDA MB-231 human breast cancer cells. Life Sci. 2008, 82:577-590.
18. Park K., Choi K., Kim H., Kim K., Lee M.H., Lee J.H., Kim Rim J.C. Isoflavone-deprived soy peptide suppresses mammary tumorigenesis by inducing apoptosis. Exp. Mol. Med. 2009, 41:371-381.
19. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55:74-108.
20. Singh M.M. Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders. Med. Res. Rev. 2001, 21:302-347.
21. Singh G., Aras S., Zea A.H., Koochekpour S., Aiyar A. Optimal transactivation by Epstein-Barr nuclear antigen 1 requires the UR1 and ATH1 domains. J. Virol. 2009, 83:4227-4235.
22. Singh G., Sinha N., Mahipag G.S. Role of apoptosis in mediating salicylic acid-induced teratogenesis in vitro. Toxicol. Mech. Methods 2009, 19:161-168.
23. Swaby R.F., Sharma C.G., Jordan V.C. SERMs for the treatment and prevention of breast cancer. Rev. Endocr. Metab. Disord. 2007, 8:229-239.
24. Tryndyak V.P., Muskhelishvili L., Kovalchuk O., Rodriguez-Juarez R., Montgomery B., Churchwell M.I., Ross S.A., Beland F.A., Pogribny I.P. Effect of long-term tamoxifen exposure on genotoxic and epigenetic changes in rat liver: implications for tamoxifen-induced hepatocarcinogenesis. Carcinogenesis 2006, 27:1713-1720.
25. Vogel V.G., Costantino J.P., Wickerham D.L., Cronin W.M., Cecchini R.S., Atkins J.N., Bevers T.B., Fehrenbacher L., Pajon E.R., Wade J.L., Robidoux A., Margolese R.G., James J., Lippman S.M., Runowicz C.D., Ganz P.A., Reis S.E., McCaskill-Stevens W., Ford L.G., Jordan V.C., Wolmark N. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006, 295:2727-2741.
26. Walker R.A. Immunohistochemical markers as predictive tools for breast cancer. J. Clin. Pathol. 2008, 61:689-696.
27. Wang T., You Q., Huang F.S., Xiang H. Recent advances in selective estrogen receptor modulators for breast cancer. Mini. Rev. Med. Chem. 2009, 9:1191-1201.
28. Williams K., Schwartz A., Corey S., Orandle M., Kennedy W., Thompson B., Alvarez X., Brown C., Gartner S., Lackner A. Proliferating cellular nuclear antigen expression as a marker of perivascular macrophages in simian immunodeficiency virus encephalitis. Am. J. Pathol. 2002, 161:575-585.